A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study

Khalili, Davood; Asgari, Samaneh; Hadaegh, Farzad; Rahimi, Kazem; Fahimfar, Noushin; Azizi, Fereidoun

doi:10.1016/j.ijcard.2015.03.067

Cited by 21 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available data addressing the effects of lipid lowering with statins on the neurocognitive function is conflicting 30 . Taken together, considering the safety aspects of statins plus the significant reduction in the risk of CVD events, benefits of statin therapy may outweigh the high proportion of people 31,32 .…”

Section: Discussionmentioning

confidence: 99%

“…First, we could not obtain participants’ information on lipid lowering therapies which can cause overestimations in our findings. In the Tehran Lipid and Glucose Study (TLGS), only 6% of the 40–75 year-old urban Iranians used lipid lowering drugs 32 . Second, we did not have detailed data on history of CHD, cerebrovascular events or peripheral vascular disease and used only prevalent CVD data that might result in the underestimation of CVD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

Asgari

Abdi

Hezaveh

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

To compare the burden of statin therapy according to the Third Adult Treatment Panel (ATP-III) and the American College of Cardiology/American Heart Association (ACC/AHA) guidelines the Survey of Risk Factors of Non-Communicable Disease (SuRFNCD)−2011of Iran was used. A survey analysis associated with sex and age categorization was run. Of total 3496 persons (1322 men) aged 40–70 years, based on the ACC/AHA guidelines, about 46.5% were eligible to receive moderate- to high-intensity statin therapy. Based on the ATP-III guidelines, 17.0% were considered as needing statin drugs. Among adults aged <60 years, the proportion of those who were eligible for statin therapy was higher (38.3%) according to the ACC/AHA guidelines compared to the ATP-III guidelines (15.2%), a difference more prominent in adults aged ≥60 years (85.2% versus 25.0%). Agreement between the two guidelines was low (kappa: 0.32). Compared to the ATP-III guidelines, the ACC/AHA guidelines increase the number of adults eligible for statin therapy in an Iraninan population from 2.5 million to 7.0 million people according to the 2011 census, specifically in those aged ≥ 60 years, a finding in agreement with those of studies from different countries.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

Asgari

Abdi

Hezaveh

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is a considerable clinical interest in identifying novel lipid biomarkers to more accurately predict cardiovascular risk and to evaluate the response to lipid-lowering therapy [1][2][3]. During the last decade, a wide array of lipid parameters have emerged substituting or adding information to the traditional biomarkers, i.e.…”

Section: Introductionmentioning

confidence: 99%

Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis

Gonzalo-Calvo¹,

Cenarro

Martínez-Bujidos

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…-Acc/aha Guideline The 2013 ACC/AHA guideline according to the Pooled Risk Equations was used to calculate the 10-year risk of hard CVD for adults aged 40-75 years. Detail for risk equation was reported elsewhere (6,25). According to this guideline, moderate to high-intensity statin therapy is recommended for individuals with prevalent CVD, those with LDL-C ≥ 190 mg/dl, diabetic patients, and non-diabetic individuals with LDL-C 70-189 mg/dl with risk score ≥ 5%.…”

Section: -Outcomesmentioning

confidence: 99%

The Role of Atherosclerotic Cardiovascular Risk Enhancers in the Prediction of Cardiovascular Events: Tehran Lipid and Glucose Study

Hadaegh

Asgari

Moosaie

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To assess the effect of the atherosclerotic cardiovascular disease risk enhancing factors (ASCVD-REFs) on incident cardiovascular disease (CVD) events among non-diabetic individuals with borderline and intermediate ACC/AHA score during 10 and 15-year follow-up. Moreover, the added value of these ASCVD-REFs on the predictive power of the pooled cohort equations (PCE) was examined. Methods: A total of 1204 adults aged 40-75 years, free from CVD at baseline with low-density lipoprotein cholesterol (LDL-C) between 70-189 mg/dl, were included. Unadjusted Cox regression analysis was used. The predictive ability of each significant ASCVD-REFs was estimated using the cut-point-free integrated discrimination improvement (IDI).Results: During 10-year follow up, 181 CVD events (including 73 hard CVD) occurred. For hard CVD events, the high blood pressure (BP) component (i.e. ≥130/85 mmHg) of metabolic syndrome (Mets) (Hazard ratio: HR (95% CI; 1.67(1.03-2.70)) and positive history of preeclampsia (5.06(1.17-22.0)) were significant ASCVD-REFs. During the longer follow-up, Mets and its components of high waist circumference (WC) and high BP significantly increased the risk. As for CVD events, the Mets and its high BP and high WC components significantly increased the risk. However, in the ACC/AHA adjusted score, these covariates did not significantly improve the predictive power of the CVD or hard CVD. Conclusions: The high BP was the most consistent and independent ASCVD-REFs in the prediction of all CVD and hard CVD, among the population with borderline/intermediate risk. Hence, considering pharmacologic therapies for patients with high BP and high LDL-C might be beneficial for preventive initiatives.

show abstract

A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study

Cited by 21 publications

References 31 publications

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis

The Role of Atherosclerotic Cardiovascular Risk Enhancers in the Prediction of Cardiovascular Events: Tehran Lipid and Glucose Study

Contact Info

Product

Resources

About